Glaucoma: Therapeutic Advances on the Cutting Edge

Glaucoma: Therapeutic Advances on the Cutting Edge

Glaucoma: Therapeutic Advances on the Cutting Edge
RestartResume

Addressing a major public health issue is challenging; good thing more treatment options are becoming available to slow the progression of glaucoma.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Glaucoma is a major public health problem in the US with an estimated 3 million Americans diagnosed with the disease and as many as 120,000 who are blind as a result. Fortunately, treatments to slow the progression of glaucoma are becoming more and more available.

    In this activity, Drs. Pradeep Ramulu and Ian Gaddie review what role these newer innovations play in improving outcomes for patients with glaucoma as well as the benefits and risks associated with these modalities.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Pradeep Y. Ramulu, MD, PhD
    Chief, Glaucoma Division
    Professor of Ophthalmology
    The Johns Hopkins Hospital
    Baltimore, MD

    Consulting Fees: Aerie Pharma, Ivantis, Théa Pharmaceuticals, W.L. Gore
    Salary: NIH 

    Faculty:
    Ian Benjamin Gaddie, OD, FAAO
    Chief Medical Officer, Keplr Vision
    Gaddie Eye Centers
    Louisville, KY 

    Consulting Fees: Aerie Pharma, Allergan, Bausch, Novartis, Sight Sciences
    Contracted Research: Aerie, Tarsus
    Ownership Interest: Leo Lens, Tarsus

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Emily Chew, MD, has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Elizabeth Lurwick has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify pharmacologic and surgical therapeutic advances in the treatment of glaucoma and the benefits and risks associated with these modalities.
    • Review clinical innovations for potential treatments of glaucoma.
  • Target Audience

    This activity is designed to meet the educational needs of ophthalmologists, optometrists, nurse practitioners, physician assistants, and ASORN members.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and National Eye Institute of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by independent educational grants from Aerie Pharma and Bausch Health.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free